CN1050504A - Magnetic medicine carrier and manufacture method thereof - Google Patents
Magnetic medicine carrier and manufacture method thereof Download PDFInfo
- Publication number
- CN1050504A CN1050504A CN 90108385 CN90108385A CN1050504A CN 1050504 A CN1050504 A CN 1050504A CN 90108385 CN90108385 CN 90108385 CN 90108385 A CN90108385 A CN 90108385A CN 1050504 A CN1050504 A CN 1050504A
- Authority
- CN
- China
- Prior art keywords
- magnetic
- carrier
- medicine
- tumor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
What the present invention relates to is the local difficult disease of treatment.Especially treat the magnetic medicine carrier and the manufacture method thereof of cancer.The carrier that obtains according to the present invention is under the effect of artificial magnet, be adsorbed on disease piece (tumor) target site specifically, long-term slow releasing pharmaceutical, reach the purpose of treatment cancer and local difficult disease, and output height, cost are low, can store at normal temperatures 2～3 years, and have clinical value and practical reference value widely.
Description
The present invention relates to the local difficult disease of a kind of treatment, especially treat the magnetic medicine carrier and the manufacture method thereof of cancer.
For treatment for cancer, mainly contain operation, radiotherapy, chemotherapy, Chinese medicine and immunization therapy several method at present.Because cancer is a kind of topical manifestations of systemic disease, so even operation and radiotherapy have very big limitation to make " super radical correction ", can not stop tumor local recur and metastasis, operation once more, radiotherapeutic effect is very poor, Chinese medicine and immunotherapy are more satisfactory to the treatment that prevents metastasis and small cancer, but to the bulk tumor of former of the part weakness that just seems.
Chemotherapy is one of main method of malignant tumor clinical treatment, chemotherapy of tumors has had bigger progress in the last thirty years, and constituted an independently subject, become one of anti-indispensable effective measure of curing oncoma, but present chemotherapy there is a fatal weakness, i.e. poison pair effect is too big, because its adopts systemic treatment, lack specificity, so often after several weeks of medication to tumor, serious poison promptly occurs and pay effect, and be forced to therapy discontinued.The general dose regimen is to the infringement of human body even bigger than the infringement of tumor itself.
Cancer therapy drug is attached to is transported to target site on the carrier again and treats tumor, be a progress greatly of chemotherapy, and realize that the key of this target is exactly the development of pharmaceutical carrier.In the last few years, the U.S., the existing people of Japan make the albumin microsphere carrier to amycin, Ismipur with the method for being heating and curing, domestic also have the people that fluorouracil is made heterogeneous plasmalogen carrier, these carriers that carry anticarcinogen all can enter in the tumor cell, but, will being eliminated by reticuloendothelial system in vivo more than 60% of above-mentioned carrier, enter tumor locus then seldom.
If can make carrier and have the magnetic response performance, after the administration, under the control of magnetic field pulse guide field, the carrier specificity that carries cancer therapy drug be confined to tumor locus, can reduce gulping down the removing of nibbling cell.This carrier of external existing artificial manufacturing has been done effort.U.S. Widder (Widder k et ol in 1979, J.Pharm Sci 68(1): 79,1979.) reported a kind of manufacture method of magnetic medicine carrier: getting human serum albumin and bovine serum albumin is the high-molecular bone frame material, the magnetic iron ore particle is magnetic material, and cancer therapy drug doxorubicin hydrochloride, add 1 milliliter of suspendible of water and be added to ultrasonic homogenize in 60 milliliters of Oleum Gossypii semens, be added to again in 110 ℃～165 ℃ the Oleum Gossypii semen and be chilled to 25 ℃ in 10 minutes, the back is frozen in 4 ℃ of storages with ether flush away Oleum Gossypii semen.This method has the high temperature process that is heating and curing, and with the physicochemical property of many medicines is damaged, only can carry several drugses such as amycin, 5-FV.Widder has also reported a kind of method that cross-linking agent is cured that adds, promptly with adding 0.2M, 2, the ether of 3-diacetyl or 0.1M formaldehyde replaces being heating and curing, and the carrier microballoons of system 0.04 gram need add 100 milliliters ether, after adding cross-linking agent curing, also need add 100 milliliters of ether and remove unnecessary cross-linking agent, make 1 gram magnetic medicine carrier, only the ether consumption just needs 9000 milliliters, manufacturing cost is too high, and also big with the chemical reagent amount of diacetyl, formaldehyde.Importantly used macromolecular scaffold material selection human serum albumin and the bovine serum albumin of prior art is substrate, cost an arm and a leg, the source is difficult for, adopt the magnetic medicine carrier of prior art manufacturing to yield poorly, need lyophilizing during storage, period of storage is no more than half a year under 4 ℃ the condition being lower than, and the magnetic medicine carrier of new system still is in animal experiment stage, is used for clinical reporting for work and does not see as yet.As the magnetic medicine carrier inalienable part,, do not propose ideal manufacture method in the prior art as yet in addition, therapeutic effect is affected even carrier produces the magnet of magnetic behavior.
Not mediocre dareing not or would not speak up, human needs be not only clinical practice, and need that performance is good, quality is high, the product of abundant amount, satisfy the treatment needs of extensive patients.
The purpose of this invention is to provide a kind of can be long time stored at normal temperatures, the manufacture method of output is high, cost is low magnetic medicine carrier.
Further purpose of the present invention provides wide, the low-cost magnetic medicine carrier of a kind of macromolecular scaffold material source.
A further object of the present invention provides the highly sensitive magnetic medicine carrier of a kind of magnetic response.
A further object of the invention provides a kind of manufacture method that makes magnetic medicine carrier produce the magnet of magnetic.
The present invention considers the manufacture method of magnetic medicine carrier:
At first be mixed and made into the pitchy glue, then surfactant and above-mentioned pitchy glue added in the dispersant, be uniformly dispersed under stirring, again below the abrupt temperature drop to 5 ℃ by high-molecular bone frame material, magnetic material, medicine, active material.
On the other hand, the present invention considers that selecting arabic gum, gelatin hydrolysate for use is the high-molecular bone frame material, to change the medium-term and long-term human serum albumin of use of prior art and this difficulty of drawing materials of bovine serum albumin, the technology of the magnetic medicine carrier of should not promote, using constitutes.
Again on the one hand, the present invention considers that selecting the containing metal material is substrate, IV family of doping II family element, and at high temperature sintering is made magnetic material, to improve the magnetic response sensitivity of magnetic medicine carrier.
Also have on the one hand, the present invention makes half mobile colloid-make magnetic medicine carrier produce the magnet of magnetic behavior with the magnetic fine particle, is embedded in disease piece (tumor) target site, makes magnetic medicine carrier be adsorbed on inside tumor and periphery rapidly and securely.
Implement method of the present invention, its abrupt temperature drop temperature is controlled at below 3 ℃, can make the molding of magnetic medicine carrier microsphere ideal, and the ratio of pitchy glue and dispersant is about 1: 4～the 6(weight ratio), the very few pitchy glue that makes of dispersant disperses to be affected, and too much will cause waste.Surfactant is 2～4%(weight ratio of dispersant).When making the pitchy glue, the weight that wherein adds active material is 1～3% of gross weight.
The high-molecular bone frame material that the present invention selects for use, arabic gum and gelatin hydrolysate, nontoxic to human body, give sheep intravenous injection 300mg/kg, observe and do not see that poison is paid in 15 months and act on, the human muscle injects 1000mg and does not see that obvious poison pays effect.These two kinds of macromolecular compounds have certain permeability, can comprise multiple medicine, can be dissolved gradually or digest and assimilate in tissue, simultaneously the medicine of parcel are emitted gradually.The magnetic medicine carrier that adopts above-mentioned two kinds of macromolecular compounds to make can be divided into can going out the drug release of parcel more than 94% of quick-releasing type and two kinds of quick-releasing types in external simulation test of spacetabs type in 12 hours, spacetabs type then in 7 days, the drug release of parcel is gone out that above two kinds of macromolecular compounds can use separately 90% or more, also can mix use by a certain percentage but will select according to the character of medicine.When concrete the application, also want strict purification, sterilization to remove thermal source and testing drug stripping curve etc.
The oxide of the optional ferrum of magnetic material of the present invention is a substrate, the II family or the IV family element of adding 1～3.5%, at high temperature sintering is made, and its particle diameter on average is about 20nmm, magnetic response is highly sensitive, external under 4000 Gausses' introduction by magnetic field operating distance reach 37cm.Toxicity is very little, mouse mainline 250mg/kg) do not see that obvious poison pays effect half a year, sheep intravenous injection 250mg/kg did not see that obvious poison paid effect in 18 months.Physicochemical property is stable, handled 24 hours and in oxirane, formaldehyde, sterilized 48 hours at 300 ℃, reach ultraviolet radiation 12 hours, its performance does not change, requirement to magnetic material substrate is to have very good magnetic response and sensitivity, and promptly use amount exceeds standard and also can not produce significantly poison pair effect to human body.In general, the conventional iron supplement total amount that the whole course of treatment, whole used iron-holder were no more than the anemia patient is removed outside the ferrum that utilizes that partly is absorbed by the body, and remaining ferromagnetic particles can excrete safely by skin, intestinal, bile, urine, antiperspirant, milk etc.The diameter of ferromagnetic particles requires below the 30nmm, is about about one of three percentages of erythrocyte diameter, and the containing metal material that can be used as magnetic material of the present invention has straight iron powder, carbonyl iron, magnetic iron ore, ferrite colloid, ferroaluminium, iron-nickel alloy, γ-Fe
2O
3, FeO, F
3O
4, BaFe
12O
19, CO-MhP etc.
The selection of medicine at first will thoroughly be got the molecular structure and the physicochemical characteristics of medicine clear, and will note and can not any chemical reaction take place with magnetic material and high-molecular bone frame material.Be applicable to that medicine of the present invention is very extensive, it comprise medicine that cancer therapy drug and other non-cancer therapy drugs are commonly used clinically most can make the carrier of this invention.The cancer therapy drug that the present invention adopts at present has fluorouracil, amycin, mitomycin, bleomycin, D actinomycin D, daunorubicin, cyclophosphamide, vincristin, Camptothecin, Ismipur AT 581., mechlorethaminoxide, thiophene for group, methotrexate, heparin, Propylenediamine Tetraacetylimide, cisplatin etc., other non-cancer therapy drugs such as Rimactazid, streptomycin, ethamine ethanol, thioacetazone and antibiotics, radiosiotope, Chinese herbal medicine, antitubercular agent etc.
Carrier content of dispersion of the present invention can reach 35% at most, and microsphere diameter is 1～25 μ m, below the A level diameter 3 μ m, can be used for intravascular administration, the B level can be used for the tumor by local administration more than 3 μ m, this carrier is under external 4000 Gausses' the action of a magnetic field, and the guiding distance reaches 25cm.
In addition, what need proposition is that when selecting the high-molecular bone frame material for use, also optional usefulness is following several: ethyl cellulose, methylcellulose, polylactic acid, polypropylene glucose, silicone starch, PVA, PVP, PEG, CAP, CMC etc.
Magnetic medicine carrier of the present invention is equivalent to " medicine guided missile ", also just like one " drug depot ", can be positioned in " warehouse " of tumor target site from this, can discharge the medicine very strong for a long time lentamente to tumor cytotoxicity power, and the high concentration and the low concentration of keeping systemic drug that can keep tumor by local very effectively, the drug distribution state of this appropriate benefit, with tumor be that a kind of topical manifestations of systemic disease is just in time coincide.It both can have been killed effectively and formerly send out cancer (effect of similar operation or radiotherapy) big, and can prevent the metastasis (the chemotherapy effect of similar whole body low concentration) of small cancer, and almost pay effect, thereby make the immunologic function of human body preciousness injury-free without any poison to human body.
Be injected into the magnetic medicine carrier microsphere of tumor target site, under the effect of guiding magnetic field, be adsorbed on around the target area rapidly, what have is penetrated in the blood vessel, what have is trapped in outside the blood vessel, the medicine that from microsphere, discharges like this, can being penetrated into to high concentration in the tumor cell wherein, some microsphere embeds between the connection of tumor cell, thereby increased the effect of nibbling that gulps down of tumor cell, rapidly cancerous cell is killed, this can not permeates cell membranes for a part of medicine and the problem that develops immunity to drugs has thus also solved in passing.
Show that from the data of reporting in recent years people's body itself also has the function of eliminating cancerous cell, and is particularly evident when immune function of human body is injury-free.But human body can be eliminated the quantity of cancerous cell and generally be no more than 1,000,000, if add the auxiliary of Chinese medicine, then may eliminate 10,000,000.Utilize magnetic medicine carrier of the present invention, after the elimination of the primary carcinoma kitchen range of local bulk, the small cancer that shifts for whole body so, the low concentration medicine that can distribute at whole body by carrier and the anti-cancer function of Chinese medicine and body itself thoroughly be eliminated, and just can realize all eliminating cancerous cell and reach the purpose of effecting a radical cure tumor.
The magnetic anticarcinogen carrier that the present invention makes especially is adapted to tumor of head and neck and neoplasmata genitalis, accounts for 25% of whole tumors, the tumor at these positions generally should not be performed the operation, and the radiotherapy sensitivity difference and the effect of paying are big, if take operative treatment, not only disfeature, and can long-term loss of function.To hepatocarcinoma, pulmonary carcinoma, osteocarcinoma, gastric cancer, esophageal carcinoma, rectal cancer also is that the indication of this carrier is better to the surface tumor effect certainly under the cooperation of some instruments (as B ultrasonic, fibrescope etc.).Say that in principle the carrier of manufacturing of the present invention all can be treated all cancers, it is the new technique that integrates operation, radiotherapy, chemotherapy three's effect.
The magnetic anticarcinogen carrier that the present invention makes, the zoopery through 2 years prove, and be not only safe and reliable, and curative effect reaches more than 88%.
Through the clinical 1 year test of giving, further proved the superiority of magnetic medicine carrier of the present invention, this carrier is very weak to Normocellular lethality, and very strong to the lethality of malignant cell, very good selectivity is promptly arranged, almost pay effect without any tangible poison to whole body.1～3 hour patient has the low hotness after administration, and other are without any sense of discomfort.During medication whole, patient's leukocyte, platelet are in range of normal value all the time, and do not have feel sick, vomiting, erythra, alopecia, bone marrow depression, headache and dizzy, have blood in stool, hematuria etc. and normal person be about the same.
Embodiment:
Get ferrum oxide 1000 grams, add II family element 15 grams, sintering is 8 hours under 700 ℃ of high temperature, pulverizes, is cleaned into the microgranule of particle diameter about 20nm.Get arabic gum 500 gram, gelatin hydrolysate 2700 grams, add active material 160 gram wet methods and synthesize aseptic, no thermal source, translucent glue, get cyclophosphamide 550 gram Bleomycin A5s 50 grams, fluorouracil 400 restrains.The active material of above-mentioned raw materials and 2% is mixed and made into the pitchy glue.Get dispersant liq paraffin wax 15000 grams then, add surfactant span 150 grams, heat gradually, add the pitchy glue, stir down and it is uniformly dispersed (700 rev/mins of rotating speeds) to 30 ℃～60 ℃.Cohesion so being cooled to below 3 ℃ at 5 minutes adds 50 milliliters of firming agent formaldehyde and different glycol then, after 50 minutes, removes dispersant and unnecessary firming agent, promptly gets the following magnetic medicine carrier of the about 8um of diameter.
Model case: patient Yao Qiaoyun, the woman, 66 years old, citizen lived No. 4 institutes in Ding Jia street, Luoyang City.February nineteen ninety self-induction palate discomfort, but pain not is obstructed to April sensation feed, April 16, existing 2.5 * 3cm was big for lump, medium hardness, inertia when checking to Luoyang City four-player people hospital (the special hospital in the former Lip river) department of stomatology.The cnidoblast that wears long learn to be checked, is diagnosed as the low-grade malignant tumor of salivary gland mucus, pathological examination numbers 3693, doctor's suggestion: operative treatment.
Because patient age is bigger, long-term hypertension 170/105mmHg and coronary heart disease are arranged again, not only disfeature after adding operation, and the forfeiture oral cavity function, so the refusal of treatment by patient.June 2 the Nikkei people make referrals to Luoyang doctor specially request treat with magnetic anticarcinogen of the present invention, this moment tumor to have 3.5 * 3.7cm big.After annotating once with this officina, tumor cell began disintegrate death in the 3rd day, and the tumor epidermis comes off gradually.During by the 7th day, obviously atrophy of tumor, after treating 6 times, tumor is complete obiteration.0.5 milliliter to 2 milliliters of each medication, weekly, the six sick inspection in week back cancerous cell feminine genders, sick inspection 90-170.Leukocyte is all the time more than 5800 during the whole medication, and whole body does not find that any poison pays effect.Patient's blood pressure stabilization, cardiac function is normal, the no any distortion of face symmetry, in a minute, diet is all normal.
For magnetic medicine carrier, some people can worry the toxic action of magnetic material to human body, and this misgivings there is no need in fact.Because magnetic carrier belongs to the slow release long-acting medicine, per 7～10 genius medications once, the content of each magnetic material only generally is no more than 0.7 gram several milligrams to tens milligrams one courses of treatment, and mainly accumulate in tumor by local, other site distribution of whole body then seldom, so do not cause tangible poison to pay effect to whole machine body.Ferromagnetic particles is except that the body absorption, and the overwhelming majority has only to form fibrosis or calcification on a small quantity in the part with discharge that comes off of the cracked cancerous cell of death, and this influences for cancer patient is little.The silicone microsphere local injection that contains ferromagnetic material of human heavy doses such as U.S. Tarner in 1975, the external use high-intensity magnetic field optionally blocks the feeding artery of tumor, make tumor ischemia necrosis, be applied to human body and do not found toxicity for many years as yet, this is consistent with practice result of the present invention.
The porous syringe needle that if can select for use Beijing match good fortune armarium company to make is clinically injected magnetic anticarcinogen of the present invention, and effect can be better.
For the problem that the clinical practice of magnetic medicine carrier also has needs to solve, make exactly magnetic medicine carrier produce magnetic behavior magnet manufacture method and how to be embedded in the concrete grammar of tumor target site.It is for referencial use that method provided by the invention can be used as clinicians: for superficial tumor or superficial part tumor, only need to make guiding magnetic field with 1～4 4000～8000 Gauss's rare-earth permanent magnetic film and get final product.Relatively difficulty is how deep tumor adds guiding magnetic field, has a magnetic field gradient problem difficult to solve here.The present invention introduces a kind of method and solves this difficult problem: earlier the permanent magnetism fine particle is made half mobile colloid (being magnet), under the monitoring of B ultrasonic or X line machine after the epidermis second positioning, with the thin puncture needle of porous permanent magnetism particle,colloid (magnet) is expelled to tumor 1～2 position, size and shape according to tumor, the magnet of artificial growth is changeable, the amount doesn't matter, both can permanently plant, also can take out over time.No matter the magnet of this artificial growth all can play good guide effect for intravascular administration or topical, and carrier will be adsorbed on inside tumor and periphery securely very short time after the body administration.The anticarcinogen that discharges in the carrier is eliminated cancerous cell exactly with high concentration rapidly.
Zoopery and clinical observation prove that only magnetic field itself just has cancer suppressing action definitely, and it can make the bioelectric potential of tumour patient be tending towards normally, thereby tumor is dwindled and obviously improve subjective symptoms.U.S. zhong hua yuan had also confirmed the therapeutical effect of permanent magnetic field to human body in 1980.For cancer patient, the permanent magnetic field of local plantation is paid effect to whole body without any tangible poison.The magnetic particle attracts each other, and can not be diffused into other position of people.Along with fibrosis, the calcification or become the NIP foreign body and wrapped up gradually of the magnetic particle,colloid of the local trace of dead cracking of cancerous cell, as excreting automatically at digestive tract by normal structure.
The present invention compared with prior art its advantage is: wide, the low price in (1) raw materials source reduces product cost greatly; (2) manufacture method adopts single aggegation to freeze the contracting method, and the production temperature is low, and little to the physicochemical property impact of medicine, properties of product are stable; (3) product not only can carry multiple oil-soluble, water-soluble or solid cancer therapy drug, also can carry the medicines such as antibiotic, anti-tubercular drug, Chinese herbal medicine, radio isotope; (4) magnetic response is highly sensitive, and under the effect of guiding magnetic field, carrier can promptly arrive and be confined to the tumour target site, greatly reduces to gulp down the removing of nibbling cell; (5) can make thousands of grams to tens thousand of grams, output is high to satisfy vast clinical tumor the need of patient at every turn; (6) can at room temperature deposit, reach 2～3 years storage period, this shows, the magnetic anti-cancer medicament carrier of manufacturing of the present invention has widely clinical value and popularization practical value.
It is worthy of note: the magnetic medicine carrier that the present invention makes can topical, also can the whole body administration, both can intramuscular injection, and also can quietly annotate, can also be oral, be applicable in principle all methods of administration.
Magnetic medicine carrier of the present invention not only can be treated various cancers, and can give desirable treatment to the difficult disease of other topical manifestations. Such as carriers of the present invention such as tuberculosis, osteomyelitis arthropathy, osteoproliferation, chronic liver disease, carbuncle, tinea, men and women's venereal disease, long-term contraception because containing ferromagnetic particles, so to radiotherapy, warming therapeutic has suitable sensibilization. As tie in, can obviously improve the result for the treatment of of radiotherapy, thermotherapy, freezing, phototherapy. If adopt carrier delivery radio isotope of the present invention59Fe、
131I、
32The irradiation that P etc. can make its radiation material that sends that tumour is carried out the long period becomes a reality, thereby receives beyond thought result for the treatment of, and starts therefrom a new field-radioactive ray magnetic treatment.
Utilize magnetic medicine carrier of the present invention, auxiliary anti-cancer function with traditional Chinese medicine excitating organism itself gets a good chance of for the radical cure cancer.
Claims (14)
1, the local difficult disease of a kind of treatment is especially treated the manufacture method of the magnetic medicine carrier of cancer, it is characterized in that:
Be mixed and made into the pitchy glue by high-molecular bone frame material, magnetic material, medicine, active material.
Surfactant and pitchy glue are joined in the dispersant, after being uniformly dispersed under stirring, below the abrupt temperature drop to 5 ℃.
2, the method for claim 1 is characterized in that: the abrupt temperature drop temperature is controlled at below 3 ℃.
3, the method for claim 1 is characterized in that: the ratio of pitchy glue and dispersant is 1: a 4～6(weight ratio).
4, the method for claim 1 is characterized in that: surfactant is 2～4%(weight ratio of dispersant).
5, the method for claim 1 is characterized in that: the weight of contained active material is 1～3% of gross weight in the pitchy glue.
6, the method for claim 1 is characterized in that: described medicine can be multiple oil-soluble, water solublity or solid cancer therapy drug.
7, the method for claim 1 is characterized in that: described medicine can be non-cancer therapy drugs such as antibiotics, radiosiotope, Chinese herbal medicine, antitubercular agent.
8, the local difficult disease of a kind of treatment is especially treated the magnetic medicine carrier of cancer, it is characterized in that: macromolecular scaffold material selection arabic gum, gelatin hydrolysate.
9, carrier as claimed in claim 8 is characterized in that: described arabic gum, gelatin hydrolysate can be distinguished use separately.
10, carrier as claimed in claim 8 is characterized in that: described arabic gum, gelatin hydrolysate mix use by a certain percentage.
11, the local difficult disease of a kind of treatment is especially treated the magnetic medicine carrier of cancer, and it is characterized in that: magnetic material is selected the containing metal material for use, doping II family or IV family element, and at high temperature sintering forms.
12, carrier as claimed in claim 11 is characterized in that: described containing metal material is the oxide of ferrum.
13, as claim 11,12 described carriers, it is characterized in that: II family or IV family element are 1～3.5% of containing metal material.
14, a kind of manufacture method that makes magnetic medicine carrier produce the magnet of magnetic, it is characterized in that: the permanent magnetism fine particle is made half mobile colloid, be embedded in disease piece (tumor) target site, make magnetic medicine carrier be adsorbed on the inside and the periphery of disease piece (tumor) securely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90108385 CN1050504A (en) | 1990-10-17 | 1990-10-17 | Magnetic medicine carrier and manufacture method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90108385 CN1050504A (en) | 1990-10-17 | 1990-10-17 | Magnetic medicine carrier and manufacture method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1050504A true CN1050504A (en) | 1991-04-10 |
Family
ID=4880970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 90108385 Pending CN1050504A (en) | 1990-10-17 | 1990-10-17 | Magnetic medicine carrier and manufacture method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1050504A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114606179A (en) * | 2020-12-04 | 2022-06-10 | 延世大学校产学协力团 | Magnetic cell for shape control of flow tube, method for producing same, flow tube shape control system, and shape control planning system |
-
1990
- 1990-10-17 CN CN 90108385 patent/CN1050504A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114606179A (en) * | 2020-12-04 | 2022-06-10 | 延世大学校产学协力团 | Magnetic cell for shape control of flow tube, method for producing same, flow tube shape control system, and shape control planning system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3176600B2 (en) | Magnetically responsive compositions for delivering bioactive substances | |
| US6652884B2 (en) | Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel | |
| Saunders et al. | The clinical testing of Ro 03-8799—pharmacokinetics, toxicology, tissue and tumor concentrations | |
| US5665393A (en) | Herbal composition for treating prostate carcinoma | |
| US10206972B2 (en) | Anti-vascular disease and antitumor pharmaceutical composition and use thereof | |
| Schubiger et al. | 90Y-resin particles—Animal experiments on pigs with regard to the introduction of superselective embolization therapy | |
| WO2010093528A2 (en) | On-demand and reversible drug release by external cue | |
| CN102125662B (en) | Compound traditional Chinese medicine for treating apoplexia and preparation method and application thereof | |
| CN1050504A (en) | Magnetic medicine carrier and manufacture method thereof | |
| CN109662968B (en) | A-nor-5 alpha androstane compound-containing leucocyte increasing preparation and application thereof | |
| CN115804842A (en) | Dacarbazine nano microneedle preparation as well as preparation method and application thereof | |
| KR20230010656A (en) | Medicines containing gold nanoparticles | |
| CN113855621A (en) | Polymer microneedle for treating acute gout attack and preparation method thereof | |
| CN113209149A (en) | Application of mitoxantrone and total ginsenoside combined medicine in preparation of medicine for treating gastric cancer | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN1939290A (en) | Medical usage of colchicine and its derivative | |
| Balkwill et al. | Effects of tumour necrosis factor on human tumour xenografts in nude mice | |
| CN114129561B (en) | Application of artemisinin drugs in preparation of drugs for preventing and treating recurrence and metastasis after tumor resection | |
| CN114369575B (en) | Brain glioma cell-derived exosome without tumor promotion function, and preparation method and application thereof | |
| CN110354299B (en) | Traditional Chinese medicine embolism microsphere for interventional therapy of middle and late liver cancer and preparation method thereof | |
| CN116687833A (en) | Soluble microneedle containing antibody-coupled albumin taxol nano-drug and preparation method and application thereof | |
| CN101176709A (en) | Beisalutin sustained-release implantation agent for curing entity tumour | |
| Hong et al. | Combined treatment of radiation and local injections of misonidazole | |
| CN100333715C (en) | Magnetic medicinal microball for directional breaking nerve back root and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |